ClinicalTrials.gg
CompletedNCT03941548Updated Apr 5, 2023Results posted

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

A Phase 2 interventional study of CTP-543 and CTP-543 Matching Placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
9th of 10
66 · median 336
Started
2019
with 2 others
Phase 2
4 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
6 of 10
Concert Pharmaceuticals

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 9th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 4th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.

Exclusion criteria

Exclusion Criteria:

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
  • Treatment with systemic medications within 3 months of screening or during the study, or biologics within 6 months of screening or during the study.
  • Clinical lab results outside the normal range.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    CTP-543 12 mg BID

    Participants received 1 x 12 milligrams (mg) CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.

    Drug: CTP-543 · Drug: CTP-543 Matching Placebo

  • Experimental
    CTP-543 24 mg QD

    Participants received 24 mg (2 x 12 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.

    Drug: CTP-543 · Drug: CTP-543 Matching Placebo

Interventions

  • Administered as 12 mg tablets.

  • DrugCTP-543 Matching Placebo

    Administered as tablets to aid treatment masking.

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Achieving at Least a 90%, 75%, and 50% Reduction in SALT Score From Baseline

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  2. Absolute Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16, 20, and 24

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  3. Relative Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16 and 20

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16 and 20

  4. Percentage of Participants With Change in Satisfaction of Hair Coverage From Baseline

    Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to Weeks 8, 12 and 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.

    Time frame: Baseline, Weeks 8, 12 and 24

Other outcomes

  1. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event.

    Time frame: From first dose up to 28 weeks

07

Results

Posted Apr 5, 2023

Participant flow

Participants were enrolled at 12 study centers in Canada and the United States from 24 May 2019 to 10 April 2020.

Participant flow — Overall Study
MilestoneCTP-543 12 mg BIDCTP-543 24 mg QD
Started3432
Safety population3432
Mitt population3432
Completed3330
Not completed12
Withdrew: Adverse event01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal of informed consent due to an adverse event10

Outcome measures

PrimaryRelative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
percent changeCTP-543 12 mg BIDCTP-543 24 mg QD
Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 2458.44 ± 34.74751.96 ± 37.887
SecondaryPercentage of Participants Achieving at Least a 90%, 75%, and 50% Reduction in SALT Score From Baseline

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 90%, 75%, and 50% Reduction in SALT Score From Baseline
percentage of participantsCTP-543 12 mg BIDCTP-543 24 mg QD
90% Reduction: Week 40.00.0
90% Reduction: Week 80.00.0
90% Reduction: Week 128.86.3
90% Reduction: Week 1620.612.5
90% Reduction: Week 2032.421.9
90% Reduction: Week 2432.431.3
75% Reduction: Week 40.00.0
75% Reduction: Week 80.00.0
75% Reduction: Week 1214.718.8
75% Reduction: Week 1623.525.0
75% Reduction: Week 2035.331.3
75% Reduction: Week 2438.234.4
50% Reduction: Week 40.00.0
50% Reduction: Week 88.80.0
50% Reduction: Week 1232.431.3
50% Reduction: Week 1644.140.6
50% Reduction: Week 2052.943.8
50% Reduction: Week 2461.853.1
SecondaryAbsolute Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16, 20, and 24

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Absolute Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16, 20, and 24
score on a scaleCTP-543 12 mg BIDCTP-543 24 mg QD
Change from Baseline at Week 41.95 ± 4.2473.02 ± 5.211
Change from Baseline at Week 811.68 ± 17.67413.61 ± 15.795
Change from Baseline at Week 1226.07 ± 28.08625.33 ± 27.874
Change from Baseline at Week 1638.83 ± 30.69931.32 ± 28.637
Change from Baseline at Week 2045.44 ± 32.16937.78 ± 31.021
Change from Baseline at Week 2448.63 ± 31.73342.82 ± 31.470
SecondaryRelative Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16 and 20

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16 and 20
Reported as:
Mean · percent change
Relative Change From Baseline in SALT Scores at Weeks 4, 8, 12, 16 and 20
percent changeCTP-543 12 mg BIDCTP-543 24 mg QD
Change from Baseline at Week 43.12 ± 7.4743.95 ± 7.126
Change from Baseline at Week 814.57 ± 19.80017.24 ± 19.034
Change from Baseline at Week 1232.10 ± 30.96031.90 ± 33.820
Change from Baseline at Week 1647.20 ± 34.66339.08 ± 35.750
Change from Baseline at Week 2054.58 ± 35.58246.24 ± 37.891
SecondaryPercentage of Participants With Change in Satisfaction of Hair Coverage From Baseline

Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to Weeks 8, 12 and 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.

Time frame:
Baseline, Weeks 8, 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Change in Satisfaction of Hair Coverage From Baseline
percentage of participantsCTP-543 12 mg BIDCTP-543 24 mg QD
Week 8: Satisfied to Satisfied3.60
Week 8: Satisfied to Dissatisfied00
Week 8: Dissatisfied to Satisfied39.344.8
Week 8: Dissatisfied to Dissatisfied57.155.2
Week 12: Satisfied to Satisfied6.50
Week 12: Satisfied to Dissatisfied00
Week 12: Dissatisfied to Satisfied35.567.7
Week 12: Dissatisfied to Dissatisfied58.132.3
Week 24: Satisfied to Satisfied6.30
Week 24: Satisfied to Dissatisfied00
Week 24: Dissatisfied to Satisfied68.870.0
Week 24: Dissatisfied to Dissatisfied25.030.0
Other pre-specifiedNumber of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event.

Time frame:
From first dose up to 28 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsCTP-543 12 mg BIDCTP-543 24 mg QD
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)2824

Adverse events

Collected over From first dose up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTP-543 12 mg BID0/34 (0%)0/34 (0%)28/34 (82.4%)
CTP-543 24 mg QD0/32 (0%)1/32 (3.1%)24/32 (75%)
Most frequent serious events
Most frequent serious events
EventCTP-543 12 mg BIDCTP-543 24 mg QD
SyncopeNervous system disorders0/341/32
Most frequent other events
Showing 10 of 25
Most frequent other events
EventCTP-543 12 mg BIDCTP-543 24 mg QD
Blood creatine phosphokinase increasedInvestigations11/344/32
Upper respiratory tract infectionGeneral disorders4/346/32
HeadacheNervous system disorders3/346/32
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/344/32
NasopharyngitisGeneral disorders4/343/32
Lipase increasedInvestigations4/341/32
AcneSkin and subcutaneous tissue disorders4/342/32
FolliculitisGeneral disorders0/343/32
Urinary tract infectionGeneral disorders1/343/32
Weight increasedInvestigations3/343/32

Baseline characteristics

Safety population included all participants who received at least one dose of study drug. Participants were summarized according to study drug regimen received.

Age, Continuous
Age, Continuous(years)CTP-543 12 mg BIDCTP-543 24 mg QDTotal
Mean38.8 ± 11.8940.4 ± 14.2039.6 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)CTP-543 12 mg BIDCTP-543 24 mg QDTotal
Female212344
Male13922
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTP-543 12 mg BIDCTP-543 24 mg QDTotal
Hispanic or Latino033
Not Hispanic or Latino342963
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CTP-543 12 mg BIDCTP-543 24 mg QDTotal
American Indian or Alaska Native011
Asian235
Native Hawaiian or Other Pacific Islander101
Black or African American448
White252348
More than one race213
Unknown or Not Reported000
Severity of Alopecia Tool (SALT) Score
Severity of Alopecia Tool (SALT) Score(score on a scale)CTP-543 12 mg BIDCTP-543 24 mg QDTotal
Mean85.77 ± 19.47387.76 ± 17.28086.73 ± 18.328
08

Study locations

12 sites
  • Colorado Center for Dermatology and Skin Surgery
    Centennial, Colorado 80111, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • SimcoDerm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Guelph Dermatology Research
    Guelph, Ontario N1L 0B7, Canada
  • Dr Wei Jing Loo Medicine Professional Corporation
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • The Centre for Clinical Trials
    Oakville, Ontario L6J 7W5, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N4, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Apr 2020, 10 months.

Results were first posted in Apr 2023, 2 years 11 months after primary completion. A results delay was requested in Mar 2021.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 8, 2019
StartActual
May 24, 2019
Primary completionActual
Apr 10, 2020
CompletionActual
Apr 10, 2020
Results delay requested
Mar 9, 2021
Results first posted
Apr 5, 2023
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03941548
Responsible party
Sponsor
First posted
May 8, 2019
Start date
May 24, 2019
Primary completion
Apr 10, 2020
Completion
Apr 10, 2020
Results posted
Apr 5, 2023
Last update
Apr 5, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion